Report
Thomas J. Schiessle
EUR 190.00 For Business Accounts Only

9M/20 spürt COVID-19 - Managementaustausch – 15.09.20 CMD (Capital Markets Day) mit Strategiewechsel?

 Die nachhaltige Trendwende und die „konsequente Kommerzialisierung“ soll unter dem seit Feb. 20 amtierenden CEO Adriaan Moelker (vormals AB Enzymes GmbH), umgesetzt (spricht profitabel) werden.

Ca. € 15 Mio. frisches Eigenkapital wurde durch eine 10 %ige Barkapitalerhöhung (zu € 8,30/neue Aktie) im Juni eingeworben. Zuvor, am 07.07.20 verließ COO Ludger Roedder aufgrund „unterschiedlicher strategischer Vorstellungen im gegenseitigen Einvernehmen mit sofortiger Wirkung“ den Vorstand.

Im 9M/19-20 verbesserte sich das EBITDA: € -0,91 Mio. (Vj.: -€ -2,3 Mio.), profitierte also vom guten Q1 + Q3. Das EPS verschlechterte sich erneut auf € -0,36 (Vj.: € -0,45). Der Cash-Bestand stieg aufgrund der KE auf € 18,8 Mio.

Underlying
Brain Biotechnology Research and Information Network AG

Brain Biotechnology Research and Information Network AG. BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company, which is active in two segments: The BioSciences segment comprises research and development activities related to replacing classical chemical and industrial processes with biotechnology processes, and the BioIndustrial segment focuses on the development of own products for both companies and consumers. The Company develops drugs, bioactive natural compounds and enzymes for customers in the chemical and pharmaceutical industries, as well as in the food and cosmetics industries. It offers research and development collaboration, as well as strategic partnerships and exclusive licensing agreements through all phases of enzyme and biological compound discovery to application development and production. The Company's product portfolio includes EvoSolution, METAGENOME, BRAINzyme, LIL, ABEL, CompActives and BioCompActives.

Provider
EQUITS GmbH
EQUITS GmbH

EQUI.TS GmbH is an innovative, equity research boutique based in Frankfurt (Germany). It is operated by its original founders and has established a reputation as a quality research provider over a period of more than 10 years. Although it generally does not focus on any particular branch of industry, its analyses often revolve around technology and growth stocks.

Analysts
Thomas J. Schiessle

Other Reports on these Companies
Other Reports from EQUITS GmbH
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch